| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£12,505,122 |
| Nicolas Loebel |
3,538,991 |
£283,119 |
| Junaid Bajwa |
1,193,697 |
£95,496 |
| Jean Duvall |
1,163,529 |
£93,082 |
| Jean Charest |
353,356 |
£28,268 |
| Carolyn Cross |
119,258,222 |
£9,540,658 |
| M&G Plc |
67,254,901 |
£5,380,392 |
| hInsight-NX, LLC |
42,272,654 |
£3,381,812 |
| Robert Cross |
37,772,652 |
£3,021,812 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,208,471 |
| CRUX Asset Management |
9,298,090 |
£743,847 |
| Chelverton Asset Management |
7,957,311 |
£636,585 |
| 09:20 |
10,000 @ 8.00p |
| 08:38 |
39 @ 7.50p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research